Johnson & Johnson has announced a decrease in sales to the tune of 7.8 percent to US$17.1 billion for the third quarter of 2015, compared to the same period in 2014. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis worldwide sales increased 5.6 percent, domestic sales increased 7.7 percent and international sales increased 3.8 percent.

Worldwide consumer sales dropped 7.7 percent to US$3.3 billion, consisting of an operational increase of 3.1 percent and a negative impact from currency of 10.8 percent. Domestic sales increased 8.9 percent, international sales dove 15.7 percent, which reflects an operational increase of 0.4 percent and a negative currency impact of 16.1 percent. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide consumer sales were up 4 percent, with domestic sales climbing 8.9 percent and international sales rising 1.5 percent.

The company pointed to positive contributions from OTC products including skin care lines Aveeno and Neutrogena, as well as oral care brand Listerine.   

“New and core products drove solid underlying growth for Johnson & Johnson in the quarter,” said Alex Gorsky, Chairman and Chief Executive Officer. “Consistent with the plans we’ve laid out for the year, we’re focusing our portfolio and are advancing our innovation agenda to expand our leadership position in key categories while seeking new opportunities for growth. Our dedicated employees are committed to improving healthcare and making a difference in the lives of patients and consumers worldwide.”